Major U.S. Policy Shift on Marijuana Moves Forward

The federal government is taking historic steps to significantly ease its restrictions on marijuana, a move that would reshape the national landscape for the cannabis industry and medical research. The action involves reclassifying the drug under federal law, acknowledging its accepted medical use.

President Donald Trump has ordered the formal review process to begin, directing officials to move cannabis from its current status as a Schedule I drug to the less restrictive Schedule III category [35268][29612]. Schedule I is reserved for substances deemed to have no accepted medical use and a high potential for abuse, such as heroin. Schedule III includes drugs with accepted medical uses and a lower abuse potential, like some prescription painkillers.

This reclassification, the most significant change to federal drug policy in over 50 years, would not legalize marijuana nationwide [29612]. However, it would dramatically reduce the tax burden on state-legal cannabis businesses by allowing them to take standard business deductions, from which they are currently barred [35268]. It would also remove major barriers to scientific research, potentially accelerating studies into the plant's medical applications [29612].

While the shift is a major victory for the cannabis industry, it creates a complex legal environment. Key federal laws would remain unchanged. Transporting marijuana across state lines would continue to be a federal crime, and individual states would retain full authority to set their own rules for legal use, sales, or prohibition within their borders [35268]. The review process itself is complex and is expected to take months to complete [35268].

The policy change stands in contrast to actions in other parts of the world. In Thailand, which became the first Asian nation to decriminalize cannabis in 2022, the government is now proposing a major reversal with a draft law that would shut down retail dispensaries and limit sales almost entirely to medical facilities [43127]. Meanwhile, in the United States, a separate federal action could threaten a different segment of the market: the 2024 Farm Bill may lead to a ban on popular hemp-derived tetrahydrocannabinol (THC) beverages currently sold in many states [11336].

The U.S. reclassification effort reflects the reality that 38 states have already legalized cannabis for medical use [29612]. It marks a fundamental departure from the long-standing federal stance that marijuana is a dangerous drug with no medical value, aligning federal policy more closely with state laws and public opinion.